Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma
Status:
Terminated
Trial end date:
2016-10-11
Target enrollment:
Participant gender:
Summary
This randomized phase I trial studies the side effects and the best dose of carfilzomib when
given together with or without romidepsin in treating patients with stage IA-IVB cutaneous
T-cell lymphoma. Carfilzomib and romidepsin may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. It is not yet known whether giving carfilzomib
alone is more effective than when given together with romidepsin.